Clinical TrialMay 22, 2026, 05:02 AM
BioNTech to Present New Oncology Clinical Data at ASCO 2026
AI Summary
BioNTech SE announced it will present new clinical data and trial updates from its late-stage oncology pipeline at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include encouraging anti-tumor activity for pumitamig in first-line non-small cell lung cancer from the ROSETTA Lung-02 trial, and durable anti-tumor activity and clinically meaningful overall survival for gotistobart in platinum-resistant ovarian cancer from the PRESERVE-004 trial. The company continues to advance its oncology pipeline with over 25 Phase 2 and Phase 3 clinical trials, including 13 pivotal trials.
Key Highlights
- Pumitamig data from Phase 2/3 ROSETTA Lung-02 trial showed encouraging anti-tumor activity in first-line non-small cell lung cancer (1L NSCLC).
- Gotistobart Phase 2 PRESERVE-004 trial data showed durable anti-tumor activity and clinically meaningful overall survival in platinum-resistant ovarian cancer (PROC).
- Pumitamig data marks the third global data set consistently showing encouraging anti-tumor activity with chemotherapy.
- Gotistobart results add to evidence supporting its potential as a chemotherapy-free treatment option.
- BioNTech's late-stage oncology pipeline includes over 25 Phase 2 and Phase 3 clinical trials.
- The pipeline features 13 ongoing pivotal trials and novel-novel combination trials.
- Two oral presentations at ASCO 2026 will highlight new data for pumitamig and gotistobart.
Price Impact
More from BNTX